Continuous infusion versus intermittent infusion of vancomycin: a systematic review and meta-analysis with a focus on nephrotoxicity, target attainment, and clinical outcomes
Related Experiment Videos
Xunuo Ma1, Leiting Xu2, Jianfei Zhang3
1Zhejiang Wanli University, Ningbo, Zhejiang, China.
Objective:
Vancomycin is widely used for Gram-positive infections but has a narrow therapeutic window and significant nephrotoxicity risk. Whether continuous infusion (CI) offers advantages over intermittent infusion (II) remains debated. We conducted a systematic review and meta-analysis to compare CI versus II vancomycin regarding nephrotoxicity, target attainment, clinical outcomes, and time to therapeutic target.
Methods:
PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to March 2026. Randomized controlled trials (RCTs) and observational studies comparing CI and II of vancomycin were included. Outcomes assessed were nephrotoxicity, target concentration attainment, clinical efficacy, microbiological clearance, mortality, and time to therapeutic target. Pooled odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random-effects models.
Results:
A total of 23 studies comprising 3,053 patients were included. CI was associated with significantly reduced nephrotoxicity (OR = 0.62, 95% CI = 0.48-0.79, I2 = 42%), higher target attainment (OR = 2.85, 95% CI = 2.12-3.84, I2 = 38%), and shorter time to therapeutic target (MD = -1.52 days, 95% CI = -1.98 to -1.06, I2 = 67%). No significant differences were observed for clinical efficacy (OR = 1.12, 95% CI = 0.86-1.46), microbiological clearance (OR = 1.08, 95% CI = 0.72-1.62), or mortality (OR = 0.94, 95% CI = 0.71-1.25).
Conclusion:
Continuous infusion of vancomycin reduces nephrotoxicity risk, improves target attainment, and shortens time to therapeutic target compared with intermittent infusion, without compromising clinical efficacy or survival. These findings support CI as a preferred strategy in patients at heightened risk of renal injury.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/view/CRD420261365683, identifier CRD420261365683.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Estimation of k and VD of Aminoglycosides
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Pharmacokinetics in Pediatric Patients: Drug Excretion
Dosage Interval and Administration Route: Determination Methods